Rezolute is trading 5.41% higher at $3.90 on October 22, 2026, diverging from broad market declines; no clear company-specific announcement or confirmed catalyst was found. - The latest identified company news was October 14, when Rezolute completed enrollment in its Phase 3 upLIFT study. - Rezolute said topline data are expected in mid-December; that earlier update does not establish the reason for the October 22 move.
🟢 Rezolute is trading 5% up
Rezolute Inc
Related News
RZLT
🔴 Rezolute is trading 5% down on October 19
RZLT
🔴 Rezolute is trading 7.2% down today as biotech weakness may contribute
RZLT
🔴 Rezolute is trading 5% down with no clear catalyst identified
RZLT
Rezolute Completes Phase 3 Enrollment for Tumor Hyperinsulinism Drug, Topline Data Expected Dec 2026
RZLT